In the Margins
French pharmaceutical company Sanofi said it will seek to replace the board of Medivation after the American drug maker’s directors rejected a $9.3 billion takeover offer. Sanofi said in April that Medivation’s directors had failed to respond to its approach. Meanwhile, Medivation’s board called the offer “inadequate,” and founder and CEO David Hung has said the French company’s move was “opportunistically timed.” Read the original story from The New York Times.
Most Read
The U.S. Supreme Court on Monday agreed to consider whether private parties should be allowed to bring claims that fund contracts violate the Investment Company Act ...
It's officially summertime, which means FBV's annual Summer Reading List is here. We curate the list each year by soliciting recommendations from our readers and friends ...
ASA Gold and Precious Metals Ltd. shareholders voted at a special meeting last week to enlarge the closed-end fund's board and elected a fifth independent director, one ...
Members of the Heartland Funds board and Heartland Advisors management team spent a recent evening together sharing a meal. Of course it's not unusual for independent ...